Big Pharma is keen on developing new treatments for chronic illnesses. After numerous stumbling blocks and failed partnerships, their subsidiary French company Sanofi have discovered something new with Warp Drive Bio Incorporated. A Harvard professor has cracked the mystery about 'molecules that drive diseases' and rendering them 'undruggable.'

It is important to take note that, in line with Big Pharma's objectives to reach the next big milestone, this huge industry is no stranger to its painful setbacks. As per the recent comprehensive report by the Wall Street Journal, percent of Big Pharma's new sales comes from drugs produced in their small companies.

Sanofi's partnership with Warp Drive Bio and the applications derived from the works of Harvard's Dr. Gregory Verdine is on the verge of discovering Big Pharma's next huge break. Dr. Verdine proposes a new way of bypassing a hurdle in curing chronic illnesses like cancer - by targeting specific proteins in the cell.

The long-term ramifications of this paradigm seem to border on science fiction. However, a related article published by Jobs & Hire also discusses the controversial argument that nanomachines (aka nanites) are 1000 times potent than current conventional drugs.

In any case, is Sanofi and Warp Drive Bio 'poking beyond the frontiers' of conventional medical knowledge? In any case, it is only a matter of time when the medical community gradually embraces new theories. Harvard's Dr. Verdine is one of the fewest credible proponents of advancement.

But despite this good news, Big Pharma must be wary of the marketing malpractices that huge industries are known for should a new miracle drug gets its approval by the Food and Drug Administration. As underscored by a report published in Financial Times, watch dogs like Competition and Markets Authority have clamped its jaws on industries like Pfizer for their tweaking their prices for anti-epilepsy drugs.